• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

快速检索引用检索图表检索高级检索

• 投稿 • 上一篇    下一篇

透骨散熏洗治疗糖尿病周围神经病变的临床研究

王学锷   

  1. 兰州军区兰州总医院安宁分院
  • 收稿日期:2017-12-24 修回日期:2017-12-24 出版日期:2018-02-25

Clinical Study of Tougusan Fumigation and Washing on the Treatment of Diabetic Peripheral Neuropathy

Wang Xuee   

  1. The tranquillity branch of the General Hospital of Lanzhou in Lanzhou Military Region
  • Received:2017-12-24 Revised:2017-12-24 Online:2018-02-25

摘要: 目的:观察透骨散熏洗疗法对糖尿病周围神经病变的临床疗效。方法:将糖尿病周围神经病变患者107例依照随机数字表单双数法分为治疗组与对照组,对照组给予基础治疗的同时口服甲钴胺片,治疗组在对照组的基础上给予透骨散熏洗,4周为一疗程,2个疗程后观察两组患者临床症状积分、Toronto临床评分、神经感觉传导速度、临床疗效。结果:2个疗程后,治疗组临床总有效率为90.57%,高于对照组的79.53%,差异有统计学意义(P<0.05);治疗组与对照组在临床症状积分、Toronto临床评分及神经感觉传导速度方面均有明显改善(P<0.05),且治疗组临床疗效优于对照组(P<0.05)。结论:基础疗法配合透骨散熏洗是治疗糖尿病周围神经病变的一种有效疗法。

Abstract: Objective:To observe the clinical curative effect of Tougusan fumigation and washing therapy on diabetic peripheral neuropathy. Methods:107 cases of patients with diabetic peripheral neuropathy, according to the method of random number tasce, were divided into the treatment group and control group. The control group was given basic treatment and oral administration of mecobalamin tablets.The treatment group was treated with Tougusan fumigation and washing based on the control group′s treatment for 4 weeks.The two groups of patients were observed with clinical symptom score,Toronto score, nerve sensory conduction velocity, clinical efficacy after 2 courses of treatment. Results: After 2 courses of treatment, the total effective rate of treatment group was 90.57%, higher than the control group 79.53%, the difference was statistically significant (P<0.05); the clinical symptom score,Toronto score and clinical nerve sensory conduction velocity of the treatment group were significantly improved than those of the control group(P<0.05), and the clinical efficacy of the treatment group was better than the control group(P<0.05). Conclusion: Basic therapy combined with Tougusan fumigation and washing is an effective treatment for diabetic peripheral neuropathy.